LB5002: SENTRY: The addition of selinexor to ruxolitinib significantly improves spleen volume reduction in patients with JAK inhibitor-naïve myelofibrosis

Myeloproliferative Neoplasms (MPNs)

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial

J Clin Oncol

Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, Harrison C, Hong J, Hou HA, Kwiatek M, Loschi M, Passamonti F, Patriarca A, Podoltsev N, Rampal R, Tantravahi S, Urian LG, Chai Y, Taverna P, Mark T, Sadiq A, Rangwala R, Vachhani P, Mascarenhas J, SENTRY Trial Investigators

doi: 10.1200/JCO-26-01080

Multiple Myeloma (MM)

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial

Br J Haematol

Delimpasi S, Špička I, Butler JP, Stevens DA, Mesa MG, Bygrave C, Merlo GM, la Porte C, Dimopoulos MA

doi: 10.1111/bjh.70479

CHICAGO 2026

Multiple Myeloma (MM)

MajesTEC-9: Teclistamab significantly improves survival outcomes in patients with RRMM

ESMO 2025

Genitourinary Cancer

POTOMAC: Durvalumab plus BCG significantly improves DFS in patients with high-risk NMIBC

Myeloproliferative Neoplasms (MPNs)

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis

Blood

Pemmaraju N, Mead AJ, Somervaille TCP, Palandri F, Koschmieder S, Delage R, Kiladjian JJ, Benton CB, Tantravahi SK, Lavi N, Yeh SP, Gomez Casares MT, Ammatuna E, McDonald AB, Yoon SS, Kirito K, Devos T, Perkins AC, Radinoff A, Sevindik OG, Bogdanovic A, Moskal R, Harb JG, Murray BC, Jiang Q, Chopra AS, Papadopoulos EJ, Potluri J, Passamonti F

doi: 10.1182/blood.2025032360

EHA 2026

Lymphoma

EPCORE DLBCL-1: Epcoritamab significantly improves PFS in patients with R/R LBCL

Myeloproliferative Neoplasms (MPNs)

Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival

Leuk Lymphoma

Kuykendall AT, Palandri F, Fillbrunn M, Liu T, Zhang S, Zhang A, Simpson R, Sajeev G, Signorovitch J, Patnaik D, Gerds AT

doi: 10.1080/10428194.2026.2628361

SABCS 2025

Breast Cancer

ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

ESMO 2025

Breast Cancer

Related content

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial

Benefit of selinexor dose reduction on outcomes with selinexor, bortezomib and dexamethasone in patients with lenalidomide-refractory multiple myeloma: Subgroup analysis of the BOSTON trial

MajesTEC-9: Teclistamab significantly improves survival outcomes in patients with RRMM

POTOMAC: Durvalumab plus BCG significantly improves DFS in patients with high-risk NMIBC

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis

EPCORE DLBCL-1: Epcoritamab significantly improves PFS in patients with R/R LBCL

Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival

ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors